# US 2019/0313957 A1 · Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0313957 A1
- Document ID: US20190313957A1
- Status: Published application
- Kind: A1
- Application number: 16/365,194
- Filed: 2019-03-26
- Published: 2019-10-17
- Earliest claimed: 2014-04-10
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Abraham Shaked; Bao-Li Chang; Brendan Keating; Toumy Guettouche
- Web page: https://patentgrep.com/patent/US20190313957A1

## CPC

- A61B 5/15: Devices for taking samples of blood
- A61B 10/0038: {Devices for taking faeces samples; Faecal examination devices (anal receptacles A61F5/451)}
- A61B 10/007: {for taking urine samples (measuring urological functions A61B5/20; genital receptacles A61F5/451; urinals for bed-ridden persons A61G9/006)}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 25/20: Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
- G16H 50/50: for simulation or modelling of medical disorders
- A61B 5/150015: {Source of blood}
- A61B 2010/0061: {Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions}
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to the discovery that the expression levels of some microRNAs (miRNAs) can use a diagnostic signature to predict transplant outcomes in a transplant recipient. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a transplant subject for acute rejection such as acute cellular rejection (ACR), methods of predicting a subject's risk of having or developing ACR and methods of assessing in a subject the likelihood of a successful or failure minimization of immunosuppression therapy (IST) dosage from standard ranges.

## Claims

### Claim 1

A method for detecting or predicting transplant rejection of a transplanted organ in a subject, the method comprising:
i. determining a level of at least three miRNAs expression in a sample from the subject, wherein the at least three miRNAs comprise SEQ ID NOs: 1-3;
ii. comparing the level of at least one miRNA in the sample from the subject relative to a baseline level in a control wherein a difference in the level of the least one miRNA in the sample from the level of the at least one miRNA in the control is indicative of an acute transplant rejection; and,
iii. wherein when acute transplant rejection is indicated, treatment for the rejection is recommended.

### Claim 2 (depends on 1)

The method of claim 1, wherein the acute transplant rejection comprises acute cellular rejection (ACR).

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise at least one selected from the group consisting of SEQ ID NOs: 4-15.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise at least one selected from the group consisting SEQ ID NOs: 16-23.

### Claim 6 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise at least one selected from the group consisting of SEQ ID NOs: 4-23.

### Claim 7 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise at least one selected from the group consisting of SEQ ID NOs: 4-23 and 97-134.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mammal is a human.

### Claim 10 (depends on 1)

The method of claim 1, wherein the level of the at least one miRNA is higher than the level of the at least one miRNA in the control by at least 1 fold.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the sample is at least one selected from the group consisting of urine, peripheral blood, serum, bile, bronchoalveolar lavage (BAL) fluid, pericardial fluid, gastrointestinal fluids, stool samples, biological fluid gathered from an anatomic area in proximity to an allograft, and biological fluid from an allograft.

### Claim 13 (depends on 1)

The method of claim 1, wherein the transplanted organ is at least one selected from the group consisting of heart, liver, lung, kidney, an intestine, pancreas, pancreatic islet cells, eye, skin, and stem cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the comparison of level of miRNA expression is computed in a regression model to indicate a trajectory of acute rejection of the transplanted organ.

### Claim at position 15

15-27. (canceled)

### Claim 28

A composition for detecting or predicting transplant rejection of a transplanted organ in a subject comprising a plurality of miRNAs consisting of SEQ ID NOs: 1-3.

### Claim 29

A composition for detecting or predicting transplant rejection of a transplanted organ in a subject comprising a plurality of miRNAs consisting of SEQ ID NOs: 1-23 and 97-134.

### Claim 30

A kit comprising:
a plurality of oligonucleotides that are configured to detect at least one miRNA from selected from the group consisting of SEQ ID NOs: 1-3.

### Claim 31 (depends on 30)

The kit of claim 30, wherein the oligonucleotides are configured to detect at least SEQ ID NOs: 1-3.

### Claim at position 20

32-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise SEQ ID NO: 15.

### Claim 38 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise SEQ ID NO: 4.

### Claim 39 (depends on 1)

The method of claim 1, wherein the at least three miRNAs further comprise SEQ ID NOs: 4 and 15.

### Claim 40 (depends on 1)

The method of claim 1, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 97-134.

### Claim 41 (depends on 1)

The method of claim 1, wherein the transplanted organ is a liver.

### Claim 42 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4-23.

### Claim 43 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4-15.

### Claim 44 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4 and 15.

### Claim 45 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4.

### Claim 46 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 15.

### Claim 47 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 16-23.

### Claim 48 (depends on 29)

The composition of claim 29, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 97-134.

### Claim 49 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4-23.

### Claim 50 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4-15.

### Claim 51 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4 and 15.

### Claim 52 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 4.

### Claim 53 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 15.

### Claim 54 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 16-23.

### Claim 55 (depends on 31)

The kit of claim 31, wherein the one or more further miRNA is selected from the group consisting of SEQ ID NOs: 97-134.
